PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : C

Records returned : 244 (on 21 Nov 2024 at 20:02:29).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
C1-Esterase inhibitor
No Information Returned
04.09.01
06.07.01
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/
04.09.01
06.07.01
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
06.07.01
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
06.07.01
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Cabotegravir
No Information Returned
Cabozantinib
No Information Returned
Caffeine
No Information Returned
Caffeine citrate
No Information Returned
Calamine
No Information Returned
Calcipotriol
No Information Returned
Calcitonin (Salmon)
No Information Returned
Calcitriol
No Information Returned
Calcium acetate
No Information Returned
Calcium acetate/magnesium carbonate
No Information Returned
Calcium carbonate
No Information Returned
Calcium carbonate and simeticone
No Information Returned
Calcium chloride
No Information Returned
Calcium folinate
No Information Returned
Calcium gluconate
No Information Returned
Calcium lactate
No Information Returned
Calcium levofolinate
No Information Returned
Calcium phosphate
No Information Returned
Calcium polystyrene sulfonate
No Information Returned
Camellia sinensis extract
No Information Returned
Canagliflozin
No Information Returned
Canagliflozin/metformin
No Information Returned
08.02.04
10.01.03
10.01.04
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.04
10.01.03
10.01.04
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centre only
08.02.04
10.01.03
10.01.04
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
02.05.05
04.07.04
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label use
02.05.05
04.07.04
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Preferred angiotensin II receptor blocker
02.05.05
04.07.04
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Preferred angiotensin II receptor blocker.
Cannabidiol
No Information Returned
04.08.01
10.02.02
Blue
Formulations :
  • Oromucosal spray
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.
04.08.01
10.02.02
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD2
CD
NHSE
Important
Specilaist initiation only.
04.08.01
10.02.02
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Specialist centres only (including ongoing supply)
04.08.01
10.02.02
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
CD
U
Capecitabine
No Information Returned
05.01.09
Red
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Antimicrobial - requires Microbiology or Respiratory Specialist Approval.
10.03.02
Green
Formulations :
  • Cream
ASPH
RSFT
SASH
SABP
Primary Care
Important
0.025% cream (Zacin brand) is licensed for this indication. (0.075% Axsain cream is NOT licensed for osteoarthritis)
10.03.02
Green (see narrative)
Formulations :
  • Cream
ASPH
RSFT
SASH
SABP
Primary Care
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
0.075% cream (Axsain brand) is licensed for this indication
10.03.02
Red
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
To be initiated by specialist pain care teams only
Capsicum
No Information Returned
02.05.05
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
02.05.05
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not 1st line
02.05.05
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Paediatric use.
02.05.05
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Paediatric use 
Carbachol
No Information Returned
04.07.03
04.08.01
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.07.03
04.08.01
Blue
Formulations :
  • Modified release tablets
  • Oral suspension
  • Suppositories
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Ensure that the patient is maintained on a specific manufacturer’s product
Carbaryl
No Information Returned
Carbenoxolone sodium
No Information Returned
Carbenoxolone sodium compound preparations
No Information Returned
07.01.01
Red
ASPH
RSFT
SASH
SABP
Primary Care
Carbidopa
No Information Returned
Carbimazole
No Information Returned
03.07.00
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Do not use in patients with active peptic ulcer disease or risk of GI bleeding.
03.07.00
Green (see narrative)
Formulations :
  • Sachets (oral solution)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Reserve for patients with swallowing difficulties (aged 15 years and over)
03.07.00
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Reserve for use in children below the age of 15 years.
11.08.01
11.08.03
Green
Formulations :
  • Eye drops
  • Eye gel
ASPH
RSFT
SASH
SABP
Primary Care
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line: Aacomer 0.2% eye gel or Aacarb Carbomer 0.2% eye gel 2nd line: Clinitas carbomer 0.2% eye gel or Lumecare carbomer 0.2% eye gel
11.08.01
11.08.03
Green
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line = Evolve Carbomer 980 prefervative free 0.2% eye gel 2nd line = Xailin 0.2% eye gel
11.08.01
11.08.03
Green (see narrative)
Formulations :
  • Eye drops (unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
Prescribe as Ocu-Lube Carbomer 0.2% Reserved for occasional use where unit dose is required (e.g. to carry in a bag)
Carbomer 940/980
No Information Returned
Carbomer 974P
No Information Returned
Carboplatin
No Information Returned
07.01.01
Red
ASPH
RSFT
SASH
SABP
Primary Care
Carglumic acid
No Information Returned
Cariprazine
No Information Returned
Carisoprodol
No Information Returned
Green
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line = AaqEye carmellose 0.5% 2nd line = Lumecare Advance Carmellose 0.5%
Green
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line = Eyeaze Carmellose 0.5% PF or VIZcellose 0.5% PF 2nd line = Carmellose 0.5% PF or Ocu-Lube
Green (see narrative)
Formulations :
  • Eye drops (unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
Prescribe as Lumecare Singles Carmellose. Reserved for occasional use where unit dose is required (e.g. to carry in a bag)
Carmustine
No Information Returned
Carteolol hydrochloride
No Information Returned
02.04.00
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
02.04.00
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
02.04.00
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
05.02.04
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Castor oil
No Information Returned
09.01.04
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
NHS England - specialist centres only
Catumaxomab
No Information Returned
05.01.02
Blue
Formulations :
  • Capsules
  • Modified release tablets
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialisit microbiology  recommendation.    Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available.  Use in primary care when indicated by microbiolgy eg on culture results,
Cefadroxil
No Information Returned
05.01.02
Green
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available
Cefamandole
No Information Returned
Cefazolin sodium
No Information Returned
05.01.02
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Antimicrobial - requires Microbiology Approval. Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available
05.01.02
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available
Green
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available
Cefoxitin sodium
No Information Returned
Cefpirome sulfate
No Information Returned
Cefpodoxime
No Information Returned
Cefprozil
No Information Returned
Cefradine
No Information Returned
05.01.02
11.03.01
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. F Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available
05.01.02
11.03.01
Red
Formulations :
  • Intraocular irrigation
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Ophthalmology specialists only
Green
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available. Primary care use restricted to IM injection to treat gonorrhoea.
Cefuroxime axetil
No Information Returned
05.01.02
11.03.01
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. Use with caution in patients with a confirmed history of penicillin rash/anaphylaxis - unless no suitable alternative is available
05.01.02
11.03.01
Red
Formulations :
  • Eye drops
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Restricted for Ophthalmology Specialists only in line with Microbiology recommendation.
5% eye drops / preservative free eye drops. Unlicensed.
05.01.02
11.03.01
Red
Formulations :
  • Intraocular irrigation
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Ophthalmology specialists only
10.01.01
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Preferred COX II inhibitor for licensed indications
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not for initiation in new patients. Existing patients may remain on therapy.
04.08.01
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
For initiation by tertiary centres only
Cerivastatin
No Information Returned
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Severe disease only
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Certoparin sodium sodium
No Information Returned
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Preferred
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
2nd line option for patients unable to swallow tablets. Loratadine 5mg/5ml sugar free oral solution (from 2 years) is the 1st-line option in this patient group
Non Formulary
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Cetomacrogol
No Information Returned
Cetrimide
No Information Returned
Cetrorelix
No Information Returned
Cetuximab
No Information Returned
Cetylpyridinium chloride
No Information Returned
Charcoal
No Information Returned
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist Centres only
Red
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist Centres only
Chlohexidine gluconate (Emollient)
No Information Returned
Chloral hydrate
No Information Returned
Chlorambucil
No Information Returned
05.01.07
11.03.01
12.01.01
Green
Formulations :
  • Eye drops
  • Eye ointment
ASPH
RSFT
SASH
SABP
Primary Care
05.01.07
11.03.01
12.01.01
Green (see narrative)
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Reserve for patients in whom a preservative free drop is necessary
05.01.07
11.03.01
12.01.01
Red
Formulations :
  • Capsules
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialisit microbiology recommendation.
Chlordiazepoxide hydrochloride
No Information Returned
Chlorhex hydrochloride
No Information Returned
Chlorhexidine acetate
No Information Returned
Chlorhexidine gluconate
No Information Returned
Chlormethine hydrochloride
No Information Returned
Chloroprocaine hydrochloride
No Information Returned
Chloroquine phosphate
No Information Returned
Chloroquine phosphate with proguanil hydrochloride
No Information Returned
Chloroquine sulfate
No Information Returned
02.02.01
Red
Formulations :
  • Oral solution
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Paediatric use. Unlicensed.
02.02.01
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Restricted to paediatrics - on specialist team recommendation. Unlicensed
Chloroxylenol
No Information Returned
Chlorphenamine maleate
No Information Returned
04.02.01
04.06.00
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
04.02.01
04.06.00
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
An option for patients with swallowing difficulties.
04.02.01
04.06.00
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Transfer to primary care only once stabilised and efficacy is established.
Chlorpropamide
No Information Returned
Chlorprothixene
No Information Returned
02.02.01
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not for initiation in new patients.
Cholera
No Information Returned
Cholesterol
No Information Returned
Cholesterol/simvastatin
No Information Returned
Cholic acid
No Information Returned
Choline salicylate
No Information Returned
09.12.00
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Choriogonadotropin alfa
No Information Returned
Chorionic gonadotrophin
No Information Returned
Ciclesonide
No Information Returned
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Blue
Formulations :
  • Eye drops (unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Important
0.1% ciclosporin (Ikervis). For dry eye disease that has not improved despite use of tear substitutes
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Red
Formulations :
  • Capsules
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Important
Ulcerative colitis only. Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Ulcerative colitis only. Prescribe by brand
Ulcerative colitis only
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Red
Formulations :
  • Eye ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
0.2% eye ointment. Specialist ophthalmology use only. Unlicensed
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
Non Formulary
Formulations :
  • Eye drops (unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Ciclosporin (Eye Anti Inflammatory)
No Information Returned
05.03.02
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Cilazapril
No Information Returned
02.06.04
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
01.03.01
Green (see narrative)
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Reserve for use where a PPI AND and other H2RAs are not suitable OR where a liquid preparation is required. Check for drug interactions.
Cinacalcet hydrochloride
No Information Returned
Cinchocaine hydrochloride
No Information Returned
02.06.04
04.06.00
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
02.12.00
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.
05.01.12
11.03.01
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation.
05.01.12
11.03.01
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
Important
Trusts to prescribe following microbiology approval only. Primary Care prescribing on specialist recommendation only.
0.3% eye drops.
05.01.12
11.03.01
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
05.01.12
11.03.01
Red
Formulations :
  • Inhalation
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
NHSE
Ciprofloxacin/fluocinolone
No Information Returned
Ciprofloxain/dexameth
No Information Returned
Cisapride
No Information Returned
Cisatracurium
No Information Returned
Cisplatin
No Information Returned
Citalopram hydrobromide
No Information Returned
Citalopram hydrochloride
No Information Returned
Citric acid monohydrate/ipecacuanha
No Information Returned
08.01.03
08.02.04
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Cladribine (Immunomodulating)
No Information Returned
05.01.05
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation.
05.01.05
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
Clemastine fumarate
No Information Returned
07.02.02
Green
Formulations :
  • Vaginal cream
ASPH
RSFT
SASH
SABP
Primary Care
Important
Refer to local antimicrobial guidelines. Oral metronidazole is as effective as topical treatment and is more cost-effective.
Blue
Formulations :
  • Capsules
  • Liquid
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. Use in primary care when indicated by microbiology eg on culture results. Clindamycin has a high association with the development of Clostridium Difficile.  Patients and carers should be advised to stop clindamycin if diarrhoea develops. 
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. Clindamycin has a high association with the development of Clostridium Difficile.  Patients and carers should be advised to stop clindamycin if diarrhoea develops.
Clindamycin hydrochloride
No Information Returned
Clindamycin phosphate
No Information Returned
Clindamycin/hydrocortisone
No Information Returned
Clindamycin/tretinoin
No Information Returned
04.08.01
Blue
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Clobetasol propionate
No Information Returned
Clobetasone butyrate
No Information Returned
Clofarabine
No Information Returned
Clofazimine
No Information Returned
Clomethiazole
No Information Returned
Clomethiazole edisilate
No Information Returned
Clomifene citrate
No Information Returned
Clomipramine hydrochloride
No Information Returned
04.08.01
04.08.02
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.08.01
04.08.02
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Rapid eye movement disorder
02.05.02
04.07.04
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Reserved for severe / resistant hypertension.
Initiation and stabilisation by the specialist before transfer of prescribing to GP.
02.05.02
04.07.04
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Unlicensed
02.05.02
04.07.04
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
02.09.00
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Preferred
02.09.00
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Cloral betaine
No Information Returned
Clorazepate dipotassium
No Information Returned
Clotiapine
No Information Returned
07.02.02
13.10.02
Green
Formulations :
  • Cream
  • Pessaries
ASPH
RSFT
SASH
SABP
Primary Care
04.02.01
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Important
Patient monitoring and registration required
Coal tar
No Information Returned
Coal tar and corticosteroid preparations
No Information Returned
Coal tar bath preparations
No Information Returned
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Co-amilozide (Amiloride hydrochloride/hydrochlorothiazide)
No Information Returned
Co-amoxiclav (Amoxicillin/clavulanic acid)
No Information Returned
04.09.01
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Co-beneldopa (Benserazide/levodopa)
No Information Returned
05.03.01
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist Approval
Cobimetinib
No Information Returned
11.07.00
15.02.01
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Cocaine (Eye)
No Information Returned
Cocaine hydrochloride
No Information Returned
04.09.01
Blue
Formulations :
  • Tablets
  • Tablets (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Red
Formulations :
  • Intestinal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
04.09.01
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Co-careldopa (Carbidopa/levodopa)
No Information Returned
04.07.01
Green (see narrative)
Formulations :
  • Effervescent tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Avoid effervescent formulations (high sodium content and more costly). Reserve for swallowing difficulties or patients with feeding tubes. Secondary Care - for A&E / discharge only.
04.07.01
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Secondary Care - for A&E / discharge only.
04.07.01
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Capsules are more costly than tablets in primary care. Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended.
Co-codamol (Codeine phosphate/paracetamol)
No Information Returned
Co-codaprin (Codeine phosphate/aspirin)
No Information Returned
Cocois
No Information Returned
Co-cyprindiol (Cyprote acetate/ethinylestradiol)
No Information Returned
Cod liver oil
No Information Returned
01.06.02
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Important
Only for use in end-of-life patients
Co-danthramer (Dantron/poloxamer 188)
No Information Returned
01.06.02
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Important
Only for use in end-of-life patients
Co-danthrusate (Dantron/docusate sodium)
No Information Returned
01.04.02
03.09.01
04.07.02
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Tablets can be dissolved in water (off-label)
01.04.02
03.09.01
04.07.02
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Tablets can be dispersed for patients with swallowing difficulties.
01.04.02
03.09.01
04.07.02
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Tablets can be dispersed for patients with swallowing difficulties. Codeine phosphate oral solution available as 25mg/5ml. Note 15mg/5ml linctus is only licensed for cough.
01.04.02
03.09.01
04.07.02
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Codeine phosphate oral solution 25mg/5ml. Codeine linctus 15mg/5ml is ONLY licensed for cough.
01.04.02
03.09.01
04.07.02
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Codeine phosphate compound mixtures
No Information Returned
Co-dergocrine mesilate
No Information Returned
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Fixed combinations are less preferred. RSCH - prescribe as separate components - combination is non-formulary at RSCH. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Fixed combinations are less preferred. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Fixed combinations are less preferred. The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
Co-dydramol (Dihydrocodeine/paracetamol)
No Information Returned
Co-fluampicil(Flucloxacillin/ampicillin)
No Information Returned
Co-flumactone (Hydroflumethiazide/spironolactone)
No Information Returned
10.01.04
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Acute gout
09.06.04
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
1,000iu tablets 50,000iu capsules
09.06.04
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
4,000iu tablets reserved for patients unable to comply with weekly dosing
09.06.04
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
50,000iu/ml oral solution in ampoules - reserved for patients unable to swallow tablets / capsules
09.06.04
Green (see narrative)
Formulations :
  • Oral drops
ASPH
RSFT
SASH
SABP
Primary Care
Important
10,000iu/ml oral drops sugar free - reserved for patients unable to swallow tablets / capsules
09.06.04
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
25,000iu tablets
01.09.01
02.12.00
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
ONLY for those with gastroenterology referral due to undiagnosed diarrhoea post-op. 2nd line. Colestyramine sachets (ordinary sachets, with sugar) are the preferred treatment option.
01.09.01
02.12.00
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
2nd line. Colestyramine sachets (ordinary sachets, with sugar) are the preferred treatment option.
01.09.01
02.12.00
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Hypercholesterolaemia. Primary care prescribing on specialist team recommendation.
Colestilan
No Information Returned
01.09.01
02.12.00
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
Important
DISCONTINUED
01.09.01
02.12.00
13.03.00
Green
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Preferred
ONLY for those with gastroenterology referral due to undiagnosed diarrhoea post-op. This is the recommended 1st line treatment option (ordinary sachets, with sugar)
01.09.01
02.12.00
13.03.00
Green (see narrative)
Formulations :
  • Sachets (SUGAR FREE powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Un
Important
ONLY for those with gastroenterology referral due to undiagnosed diarrhoea post-op AND are diabetic who request a sugar free formulation. The ordinary powder sachets are 1st line.
01.09.01
02.12.00
13.03.00
Blue
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Preferred
These are the recommended 1st line treatment option (ordinary sachets, with sugar)
01.09.01
02.12.00
13.03.00
Blue
Formulations :
  • Sachets (SUGAR FREE powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Un
Important
3rd line colestyramine (sugar free) – for diabetic patients who request a sugar free formulation. Most costly preparation. The ordinary powder sachets are 1st line.
01.09.01
02.12.00
13.03.00
Blue
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Important
GP may prescribe on specialist recommendation.
01.09.01
02.12.00
13.03.00
Blue
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Diarrhoea associated with Crohn's disease, ileal resection, vagotomy, diabetic vagal neuropathy and radiation
GP may initiate on specialist recommendation.
01.09.01
02.12.00
13.03.00
Blue
Formulations :
  • Sachets (SUGAR FREE powder)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Diarrhoea associated with Crohn's disease, ileal resection, vagotomy, diabetic vagal neuropathy and radiation
GP may initiate on specialist recommendation. Reserve the sugar-free sachets for diabetic patients on request.
01.09.01
02.12.00
13.03.00
Blue
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Hypercholesterolaemia. Primary care prescribing on specialist team recommendation.
Colistimeth sodium
No Information Returned
Blue
Formulations :
  • Powder
ASPH
RSFT
SASH
SABP
Primary Care
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialisit microbiology recommendation. Colistimethate sdoium 1million unit powder for solution for injection, infusion, inhalation vials is the most cost effective option for inhalation use by nebulisation.
Red
Formulations :
  • Inhalation
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
Colistin sulfate
No Information Returned
Green
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Combined ethinylestradiol 20mcg
No Information Returned
Combined ethinylestradiol 30mcg
No Information Returned
Combined ethinylestradiol 35mcg
No Information Returned
Combined ethinylestradiol 50mcg
No Information Returned
Combined mestranol
No Information Returned
Co-methiamol (Methionine/paracetamol)
No Information Returned
Compound alginates and proprietary indigestion preparations
No Information Returned
Compound antispasmodic preparations
No Information Returned
Compound iron preparations
No Information Returned
Co-phenotrope (Diphenox hydrochloride/atropine sulfate)
No Information Returned
Co-prenozide (Oxprenolol hydrochloride/cyclopenthiazide)
No Information Returned
Co-proxamol (Dextropropoxyphene hydrochloride/paracetamol)
No Information Returned
Corifollitropin alfa
No Information Returned
Coronavirus vaccine
No Information Returned
Corticosteroids
No Information Returned
Corticotropin
No Information Returned
Cortisone acetate
No Information Returned
Co-simalcite (Simeticone/hydrotalcite)
No Information Returned
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Co-triamterzide(Triamterene/hydrochlorothiazide)
No Information Returned
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Follow local guidelines on the use of antimicrobials.
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Important
Follow local guidelines on the use of antimicrobials.
Co-zidocapt (Hydrochlorothiazide/captopril)
No Information Returned
Crisantaspase
No Information Returned
Crotamiton
No Information Returned
Cyanocobalamin
No Information Returned
Green
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Green
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
Green
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
On request from the specialist / Cancer Centre.
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Red
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Cyclizine lactate
No Information Returned
Cyclopenthiazide
No Information Returned
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Important
Eye drops 0.5%, 1%. Transfer to primary care may be suitable after a minimum of 2 months supply from the specialist.
Red
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Important
eye drops 0.5%, 1%
Cyclophosphamide
No Information Returned
05.01.09
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Antimicrobial - requires Microbiology or Respiratory Specialist Approval.
Cyproheptadine hydrochloride
No Information Returned
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Cystine
No Information Returned
Cytarabine
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More